tyrosine-kinase inhibitor

OncoDaily

News Feed Opinion Career Insight Dialogues Blog Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

November, 2024

tyrosine-kinase inhibitor

Sep 2, 2024, 03:41 | Insight

FDA Grants Zongertinib Breakthrough Therapy Designation in HER2-Mutant NSCLC

The FDA has recently granted Zongertinib, a HER2-specific tyrosine kinase inhibitor (TKI), Breakthrough Therapy Designation…

Apr 14, 2024, 22:26 | Insight

Sergio Cifuentes Canaval: Wu Y-L et al. have just released the results of a preplanned interim analysis from the ALINA trial

Sergio Cifuentes Canaval, Cancer Research Project Manager at CENEIT México, shared a post on LinkedIn:…

Apr 12, 2024, 10:05 | Drugs

Piotr J. Wysocki: Immunotherapy combined with tyrosine-kinase inhibitor is not better than docetaxel in NSCLS patients after first-line chemoimmunotherapy failure

Piotr J. Wysocki, Head of the Oncology Department at the University Hospital Krakow, shared a post…

All: 3 Posts: 1 - 100

Dr. Richard Pazdur: 25 Years of Transforming Oncology Drug Development at the FDA

New €4.9m Beaumont RCSI Cancer Centre and Irish Cancer Society Partnership to Transform Lung Cancer Care in Ireland

Biden Cancer Moonshot Initiative Awards Over $6 Million to 11 Early-Career Researchers for Innovative Cancer Research

Immunotherapy for Melanoma: Types, Success Rate, Side Effects & More

Tom Green and Testicular Cancer: How He Went Against, How He Survived, and More

Special Coverage

ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023